| Secondary |
| Hypertension |
46.1% |
| Drug Use For Unknown Indication |
16.7% |
| Type 2 Diabetes Mellitus |
7.6% |
| Hyperlipidaemia |
3.2% |
| Atrial Fibrillation |
2.5% |
| Cardiac Failure |
2.5% |
| Constipation |
1.9% |
| Diabetes Mellitus |
1.9% |
| Osteoporosis |
1.9% |
| Restlessness |
1.9% |
| Epilepsy |
1.6% |
| Maternal Exposure Timing Unspecified |
1.6% |
| Product Used For Unknown Indication |
1.6% |
| Sleep Disorder |
1.6% |
| Thrombosis Prophylaxis |
1.6% |
| Foetal Exposure During Pregnancy |
1.3% |
| Hiv Infection |
1.3% |
| Pain |
1.3% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.3% |
| Convulsion Prophylaxis |
0.9% |
|
| Hypertensive Crisis |
15.6% |
| Pneumonia |
14.1% |
| Red Blood Cell Sedimentation Rate Increased |
12.5% |
| Infection |
9.4% |
| Supernumerary Nipple |
9.4% |
| Stevens-johnson Syndrome |
4.7% |
| Hepatic Necrosis |
3.1% |
| Medication Error |
3.1% |
| Presyncope |
3.1% |
| Psoriasis |
3.1% |
| Qrs Axis Abnormal |
3.1% |
| Swelling Face |
3.1% |
| Syncope |
3.1% |
| Tongue Neoplasm Malignant Stage Unspecified |
3.1% |
| Accidental Exposure To Product |
1.6% |
| Accidental Overdose |
1.6% |
| Atrial Fibrillation |
1.6% |
| Blood Pressure Diastolic Decreased |
1.6% |
| Heart Rate Decreased |
1.6% |
| Lenticular Opacities |
1.6% |
|
| Concomitant |
| Hypertension |
39.7% |
| Product Used For Unknown Indication |
14.6% |
| Drug Use For Unknown Indication |
7.2% |
| Type 2 Diabetes Mellitus |
6.4% |
| Coronary Artery Disease |
4.7% |
| Atrial Fibrillation |
3.5% |
| Diabetes Mellitus |
2.7% |
| Prophylaxis |
2.6% |
| Rheumatoid Arthritis |
2.3% |
| Renal Transplant |
1.9% |
| Parkinson's Disease |
1.8% |
| Pain |
1.7% |
| Hypercholesterolaemia |
1.6% |
| Metastatic Renal Cell Carcinoma |
1.6% |
| Chronic Obstructive Pulmonary Disease |
1.4% |
| Renal Failure |
1.4% |
| Depression |
1.3% |
| Hyperlipidaemia |
1.2% |
| Pneumonia |
1.2% |
| Osteoporosis |
1.1% |
|
| Vomiting |
14.6% |
| Syncope |
9.0% |
| White Blood Cell Count Decreased |
7.6% |
| Renal Impairment |
6.9% |
| Shock Hypoglycaemic |
6.9% |
| Weight Decreased |
6.3% |
| Death |
4.9% |
| Hyperglycaemia |
4.9% |
| Renal Failure |
4.9% |
| Hyponatraemia |
4.2% |
| Pneumonia |
3.5% |
| Pulmonary Embolism |
3.5% |
| Rash Generalised |
3.5% |
| Clostridium Difficile Colitis |
2.8% |
| Drug Interaction |
2.8% |
| General Physical Health Deterioration |
2.8% |
| Hypertension |
2.8% |
| Lung Neoplasm Malignant |
2.8% |
| Proteinuria |
2.8% |
| Sick Sinus Syndrome |
2.8% |
|
| Interacting |
| Atrial Fibrillation |
20.0% |
| Benign Prostatic Hyperplasia |
20.0% |
| Hypertension |
20.0% |
| Ischaemic Heart Disease Prophylaxis |
20.0% |
| Parkinson's Disease |
20.0% |
|
|
